| Solifenacin at 3 years: a review of efficacy and safety. | |
| | |
MedLine Citation:
|
PMID: 18654073 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
Now on the market in the United States for almost 3 years and available in 48 countries worldwide, solifenacin 5 mg or 10 mg once daily continues to demonstrate a profile of safety and efficacy as a treatment for incontinence, urgency, and other symptoms of OAB. More than 2.2 million patients have been treated worldwide with solifenacin. Safety and efficacy data across numerous studies in several thousand patients, along with flexible dosing, support the use of this agent as a first-line antimuscarinic treatment for OAB. Data from large randomized controlled trials such as VENUS and STAR show statistically significant superiority compared with placebo and improved outcomes over those achieved with tolterodine ER 4 mg. Solifenacin is an agent of choice for OAB-related incontinence, with more than 50% of incontinent patients reporting no incontinence episodes after 12 weeks of solifenacin therapy. In addition to improved efficacy, solifenacin offers good tolerability with a low incidence of side effects. Once-daily, flexible dosing with this agent provides 24-hour control of OAB symptoms and significantly increases warning time (the period from onset of urgency to voiding), which may also increase a patient's chance of avoiding episodes of incontinence. |
| | |
Authors:
|
Richard S Pelman; James P Capo; Sergio Forero-Schwanhaeuser |
Related Documents
:
|
19697083 - The management of cough: a clinical year in review. 21044633 - Positional information and patterning revisited. 21974773 - Hand warmer related corrosive injury. |
Publication Detail:
|
Type: Journal Article; Review |
Journal Detail:
|
Title: Postgraduate medicine Volume: 120 ISSN: 1941-9260 ISO Abbreviation: Postgrad Med Publication Date: 2008 Jul |
Date Detail:
|
Created Date: 2008-07-25 Completed Date: 2008-10-21 Revised Date: 2009-02-12 |
Medline Journal Info:
|
Nlm Unique ID: 0401147 Medline TA: Postgrad Med Country: United States |
Other Details:
|
Languages: eng Pagination: 85-91 Citation Subset: AIM; IM |
Affiliation:
|
Bellevue Urology Associates, Bellevue, WA 98004, USA. rpelman@bellevueurology.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Aged, 80 and over Drug Administration Schedule Humans Middle Aged Muscarinic Antagonists / pharmacokinetics, therapeutic use* Quinuclidines / pharmacokinetics, therapeutic use* Tetrahydroisoquinolines / pharmacokinetics, therapeutic use* Treatment Outcome Urinary Bladder, Overactive / drug therapy*, etiology, physiopathology |
| Chemical | |
Reg. No./Substance:
|
0/Muscarinic Antagonists; 0/Quinuclidines; 0/Tetrahydroisoquinolines; 0/quinuclidin-3'-yl-1-phenyl-1,2,3,4-tetrahydroisoquinoline-2-carboxylate monosuccinate |
| Comments/Corrections | |
Comment In:
|
Postgrad Med. 2008 Nov;120(4):107-8
[PMID:
19020373
]
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Human papillomavirus, cervical cancer, and the vaccines.
Next Document: Dispelling the myths about omega-3 fatty acids.